title: Oral calcium carbonate administration ameliorates the progression of renal failure in rats with hypertension.
abstract: Oral calcium supplementation is reported to have phosphate-binding and antihypertensive effects. Since both phosphate binders and antihypertensive agents are reported to attenuate renal injury, we studied the effect of oral calcium carbonate (CaCO3) administration on the course of renal deterioration using doxorubicin-induced renal failure in rats treated with deoxycorticosterone acetate and salt for 10 weeks. Rats were divided into four groups: the CaCO3 (6.0 g/kg/d) group (n = 12), the aluminum hydroxide (Al(OH)3; 6.0 g/kg/d) group (n = 11, as a phosphate-binder control), the hydralazine (10 mg/kg/d) group (n = 11, as an antihypertensive control), and the control group (n = 12). All agents were given as a mixed chow diet. Blood pressure and urinary protein excretion progressively increased in the control rats. CaCO3 and hydralazine lowered blood pressure, but Al(OH)3 did not (185 +/- 4 mm Hg, control; 160 +/- 5 mm Hg, CaCO3; 171 +/- 8 mm Hg, Al(OH)3; 156 +/- 5 mm Hg, hydralazine at week 10). Proteinuria was reduced in the rats treated with CaCO3 and Al(OH)3 compared with those without the treatment (986 +/- 86 mg/d, control; 551 +/- 54 mg/d, CaCO3; 527 +/- 31 mg/d, Al(OH)3; and 955 +/- 68 mg/d, hydralazine at week 10). Serum phosphate concentration and calcium phosphate products also were significantly lower in both the CaCO3 and Al(OH)3 groups than in the control group. At week 10, increased serum urea nitrogen, impaired renal function, and glomerular sclerosis present in the control group were significantly attenuated in both in the CaCO3 and Al(OH)3 groups.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Nakamura
authors.forename: H
authors.initials: H
authors.lastname: Suzuki
authors.forename: Y
authors.initials: Y
authors.lastname: Ohno
authors.forename: A
authors.initials: A
authors.lastname: Ohishi
authors.forename: H
authors.initials: H
authors.lastname: Yamakawa
authors.forename: H
authors.initials: H
authors.lastname: Okada
authors.forename: T
authors.initials: T
authors.lastname: Saruta
mesh_terms: D000284:Administration, Oral; D000536:Aluminum Hydroxide / Q000627:therapeutic use; D000818:Animals; D002119:Calcium Carbonate / Q000008:administration & dosage / Q000627:therapeutic use*; D003900:Desoxycorticosterone; D004317:Doxorubicin; D006830:Hydralazine / Q000627:therapeutic use; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy; D007676:Kidney Failure, Chronic / Q000139:chemically induced / Q000517:prevention & control*; D008297:Male; D010710:Phosphates / Q000097:blood; D051381:Rats; D017208:Rats, Wistar; D012982:Sodium, Dietary
chemical_list: D010710:Phosphates; D012982:Sodium, Dietary; D006830:Hydralazine; D003900:Desoxycorticosterone; D000536:Aluminum Hydroxide; D004317:Doxorubicin; D002119:Calcium Carbonate